부산대학교 도서관

It is estimated that as of 2019, ~463 million adults were living with diabetes mellitus.[1] Approximately 93 million of those patients have some degree of diabetic retinopathy, and up to 10% have vision-threatening disease.[1] These staggering numbers are expected to continue to increase, making the optimal management of the most sight-threatening form of the disease, proliferative diabetic retinopathy (PDR), a subject of continued debate. Although PRP alone was once the mainstay of PDR treatment, the advent of highly effective anti-VEGF agents and the introduction of small-gauge vitrectomy, as well as other surgical advances will continue to shift the balance to favor a combined approach to treatment in most patients. In a report of patient-centered outcomes comparing ranibizumab and PRP for PDR, Beaulieu et al[16] found that over 2 years, 97% of ranibizumab patients retained at least 20/40 or better vision in at least 1 eye compared with 87% of PRP patients. Treatments in the coming decades will likely continue to reflect not only the role of technological advances and improvements in treatment but also will take into account quality of life and cost considerations, individual patient decision-making, and patient-specific anatomic and demographic characteristics. [Extracted from the article]